Leading The Way In Pediatric Endo-Cannabinoid Medicine

Phyto Therapeutic Medicine for Inflammatory Conditions

Initial 2.2 Million Square Feet of Cultivation

Exclusive Clinically Validated Formulations

Innovation in Skin Care and Anti-Aging Systems

Relevium Announces Results of Annual Meeting of Shareholders and Updates Other Regulatory Matters

MONTREAL, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the results of the Company's annual general and special meeting (the "AGM") held...

Relevium Announces Record Sales From the Bioganix® Brand and Provides CBD Update

MONTREAL, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company hit a record high in monthly sales in the month of July 2019 for its...

Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

MONTREAL, July 10, 2019 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which...

Relevium Technologies

Relevium is a publicly traded corporation strategically focused on the expansion and acquisition of entrepreneurial brands within the health and wellness sector. Our focus is on being a trusted source of high-quality nutraceutical and CBD products.

Subscribe to our Newsletter

You have Successfully Subscribed!